TIAP Launches Next Generation Program to Support Early-Stage Drug Development

LAB150-NextGen to offer up to $1.6M USD per project to advance new drug candidates

Building on the success of its LAB150 Program, TIAP has announced a new iteration of the program — LAB150-NextGen to support the advancement and commercialization of drug development projects and technologies within TIAP’s member academic institutions.

LAB150-NextGen is a drug development program that supports the advancement and commercialization of research projects and technologies in the Toronto biomedical ecosystem with the twin goals of building new drug candidates and launching new Ontario-based biotechnology companies.

The deadline for the initial intake period is June 30, 2025.